Lead Product(s): BNT211
Therapeutic Area: Oncology
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2020
The data for BNT211 reports Claudin 6 as a novel target for CAR-T cell therapy of solid tumors and introduces CARVac, a new RNA vaccine promoting the amplification of CAR-T cells in vivo.